Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD
-
New data shows long-term use of an AID system powered by
Dexcom CGM can safely maintain improvements in glycaemic outcomes for up to two years1. -
Real-world evidence demonstrates reduction in severe hypoglycaemia and diabetic ketoacidosis over 12 months in people with Type 1 diabetes using a
Dexcom -powered Automated Insulin Delivery (AID) system2. - New global user data analysis shows an association between Dexcom CGM usage and a meaningful reduction in HbA1c for people treating their T2D with a GLP-14.
-
Dexcom continues to enhance access to its portfolio around the world, including swift roll out of Dexcom ONE+ and the now, FDA cleared, Direct-to-Watch feature for G7.
“As the pioneer in biosensing, since last year’s ATTD,
Driving access to best-in-class CGM technology
Delivering exceptional end-user experiences with direct connectivity to Apple Watch
Showing a commitment to not only expanding access to life-changing CGM but also to improving the experience for those already using Dexcom CGM,
Unparalleled AID abilities
With robust clinical evidence and strong partner relationships, Dexcom’s pioneering leadership and capabilities within connected systems remains unparalleled. Of particular significance within AID systems, the clinically meaningful health outcomes resulting from use of both the Tandem t:slim X2 insulin pump with Control-IQ technology and Insulet Omnipod 5 are only proven when powered by Dexcom CGM. Further demonstrating the value of AID systems powered by Dexcom CGM,
Furthermore, real-world evidence from almost 3,000 people using a Tandem Control-IQ AID system, powered by Dexcom CGM, demonstrated lower rates for both severe hypoglycaemia and diabetic ketoacidosis over 12 months compared to historic rates2. Concurrent with these lower rates, on average adult participants spent more than 70% CGM time in range, while paediatric participants achieved 60% CGM time in range.
In December,
Exceptionally effective CGM for all types of diabetes
As demonstrated in multiple symposia and presentations at ATTD this year, clinical evidence continues to build demonstrating the effectiveness of Dexcom CGM use amongst people with all types of diabetes. Of particular note,
“The breadth of studies and outcomes showcased here at ATTD demonstrates the crucial role that Dexcom CGM can play in the treatment of Type 2 diabetes,” said Dr
About
†Compatible smartphone is required to pair a new Dexcom G7 sensor with an Apple Watch. Dexcom G7 users must continuously have their smartphone within 20 feet / 6 meters to utilize the Share/Follow features. Apple Watch is not capable of Share/Follow.
* Any insulin: CGM (-0.64%) vs control (-0.25%), p<0.0001. NIT: (-0.63%) CGM vs control (-0.14%), p<0.0001
++ As of Feb., 2024. Data on file, Tandem Diabetes Care.
‡ Risk for mortality was significantly lower in both T1D CGM users (
1 Criego A B et al. Two Years with a Tubeless Automated Insulin Delivery System:A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics. 2024. 26(2) 2 Graham, R et al. Real-World Use of Control-IQ Technology is Associated with a
Dexcom Symposia Overview – 2024
Dexcom Innovation: AID, Smart Devices and EHR Integration for Enhanced Care
Moderated by Professor
-
This expert panel will speak to the latest on automated insulin delivery (AID), connected smart devices and electronic health record (EHR) integrations. We will shed light on the latest innovations with Dexcom CGM and the evidence expanding AID opportunities for people living with type 1 diabetes, including pregnant women. Additionally, we will discuss late breaking evidence highlighting improved outcomes with
Dexcom -powered AID systems. We’ll also share the latest advancements in the product pipeline focused on improving the patient experience and glycemic outcomes with integrated diabetes technologies. Finally, we will highlight recent developments with Dexcom’s direct integration into the EHR designed to improve workflow and enable healthcare professionals to enhance patient interactions and care.
Dexcom Breakthroughs: Leveraging CGM Early and Across the Spectrum of Type 2 Diabetes Care
Moderated by
-
Dexcom has led the development of evidence to support the use of Dexcom CGM in people with type 2 diabetes, highlighting the role of CGM for early glycemic goal achievement for effective T2D management. In this session you’ll be the first to learn about Dexcom’s newest system, Dexcom ONE+! We’ll dive into compelling data illustratingDexcom's pivotal role in optimizing outcomes for individuals across the T2D spectrum and the profound influence on enhancing glycemic management. We’ll expand the journey to include an examination of time in tight range, exploring the nuanced understanding of the metric. Additionally, we’ll explore data demonstrating the synergistic effects of Dexcom CGM combined with GLP-1 receptor agonists, shedding light on how the combination contributes to a comprehensive approach to care.Dexcom has a multifaceted role in early intervention and personalized strategies for T2D.
Dexcom Transformation: Improving Lives of People with Type 2 Diabetes
Moderated by
-
Explore the cutting-edge of CGM technology with
Dexcom , featuring a comprehensive portfolio of CGM products including the new Dexcom ONE+ system. Join a dynamic conversation, moderated by Dr.William Polonsky , PhD, CDCES, as experts delve into the transformative impact of real-time CGM for people with type 2 diabetes. Uncover a dual perspective, examining both the attainment of clinical goals as well as qualitative, patient-reported outcomes that spotlight how individuals leverage Dexcom CGM to successfully understand the impact of lifestyle choices that help inform personalized diabetes management goals.
For more information about these presentations and to register to virtually attend the conference, visit https://attd.kenes.com/ .
Category: IR
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305323546/en/
Media Contact
+44 (0) 7552 368398
gemma.mcdonald@dexcom.com
Investor Contact
858-203-6657
sean.christensen@dexcom.com
Source: